doi:10.3969/j.issn.1004-583X.2025.01.014

Abstract

CLC Number:

R593.22

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2025.01.014

https://huicui.hebmu.edu.cn/EN/Y2025/V40/I1/86

References 35

[1]	司慧敏. 类风湿关节炎患者80例共病现象的临床特点及相关因素分析[J]. 中国社区医师, 2019, 35(36): 86-87.
[2]	杨显娜, 包路艳, 唐海倩, 等. 4238例类风湿关节炎共病的临床研究[J]. 风湿病与关节炎, 2022, 11(7): 18-23.
[3]	北京协和医院国家皮肤与免疫疾病临床医学研究中心, 中国医师协会风湿免疫专科医师分会, 中国康复医学会风湿免疫病康复专业委员会, 等. 2024中国类风湿关节炎诊疗指南[J]. 中华内科杂志, 2024, 63(11): 1059-1077.
[4]	Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: Results of an international, cross-sectional study (COMORA)[J]. Ann Rheum Dis, 2014, 73(1): 62-68.
[5]	杜红丽, 陈运转. 类风湿关节炎患者共存疾病的临床特征及危险因素分析[J]. 黑龙江医学, 2021, 45(19): 2040-2041.
[6]	周珍妮, 李芳, 黄德益, 等. 类风湿关节炎患者223例共病现象的临床特征及其相关因素分析[J]. 中国全科医学, 2017, 20(18): 2201-2207. doi: 10.3969/j.issn.1007-9572.2017.18.007
[7]	Park E, Bathon J. Cardiovascular complications of rheumatoid arthritis[J]. Curr Opin Rheumatol, 2024, 36(3): 209-216. doi: 10.1097/BOR.0000000000001004 pmid: 38334476
[8]	Kerola AM, Kerola T, Kauppi MJ, et al. Cardiovascular comorbidities antedating the diagnosis of rheumatoid arthritis[J]. Ann Rheum Dis, 2013, 72(11): 1826-1829. doi: 10.1136/annrheumdis-2012-202398 pmid: 23178207
[9]	Giles JT, Post WS, Blumenthal RS, et al. Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis[J]. Arthritis & Rheumatism, 2011, 63(11): 3216-3225.
[10]	Tinggaard AB, de Thurah A, Andersen IT, et al. Rheumatoid arthritis as a risk factor for coronary artery calcification and obstructive coronary artery disease in patients with chest pain: A registry based cross-sectional study[J]. Clin Epidemiol, 2020, 12: 679-689. doi: 10.2147/CLEP.S251168 pmid: 32612393
[11]	Cioffi G, Ognibeni F, Dalbeni A, et al. High prevalence of occult heart disease in normotensive patients with rheumatoid arthritis[J]. Clin Cardiol, 2018, 41(6): 736-743. doi: 10.1002/clc.22926 pmid: 29869800
[12]	Figus FA, Piga M, Azzolin I, et al. Rheumatoid arthritis: Extra-articular manifestations and comorbidities[J]. Autoimmun Rev, 2021, 20(4): 102776.
[13]	Wu D, Luo Y, Li T, et al. Systemic complications of rheumatoid arthritis: Focus on pathogenesis and treatment[J]. Front Immunol, 2022, 13: 1051082.
[14]	Koduri G, Solomon JJ. Identification, monitoring, and management of rheumatoid arthritis-associated interstitial lung disease[J]. Arthritis Rheumatol, 2023, 75(12): 2067-2077.
[15]	Hanai S, Kobayashi Y, Ito R, et al. Methotrexate-associated pneumonitis[J]. QJM, 2022, 115(5): 305-307. doi: 10.1093/qjmed/hcac068 pmid: 35253857
[16]	Barrera P, Laan RF, van Riel PL, et al. Methotrexate-related pulmonary complications in rheumatoid arthritis[J]. Ann Rheum Dis, 1994, 53(7): 434-439. pmid: 7944614
[17]	Akiyama M, Kaneko Y. Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease[J]. Autoimmun Rev, 2022, 21(5): 103056.
[18]	Lodder MC, de Jong Z, Kostense PJ, et al. Bone mineral density in patients with rheumatoid arthritis: Relation between disease severity and low bone mineral density[J]. Ann Rheum Dis, 2004, 63(12): 1576-1580. doi: 10.1136/ard.2003.016253 pmid: 15547081
[19]	Cagnetta V, Patella V. The role of the immune system in the physiopathology of osteoporosis[J]. Clin Cases Miner Bone Metab, 2012, 9(2): 85-88.
[20]	Liu Y, Liu Y, Chen Z, et al. Rheumatoid arthritis and osteoporosis: A bi-directional Mendelian randomization study[J]. Aging (Albany NY), 2021, 13(10): 14109-14130.
[21]	van Staa TP, Geusens P, Bijlsma JWJ, et al. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis[J]. Arthritis Rheum, 2006, 54(10): 3104-3112.
[22]	Minaur NJ, Kounali D, Vedi S, et al. Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density[J]. Rheumatology (Oxford), 2002, 41(7): 741-749.
[23]	Liu XZ, Gao Y, Fan J, et al. Metabolic abnormalities in rheumatoid arthritis patients with comorbid diabetes mellitus[J]. Clin Rheumatol, 2018, 37(1): 219-226. doi: 10.1007/s10067-017-3847-7 pmid: 28944421
[24]	Baker JF, England BR, George M, et al. Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis[J]. Ann Rheum Dis, 2021, 80(5): 566-572. doi: 10.1136/annrheumdis-2020-219140 pmid: 33397733
[25]	邹燕, 吴宪鸣, 徐兰, 等. 白芍总苷胶囊联合硫酸羟氯喹片治疗T2DM合并类风湿性关节炎的临床效果观察[J]. 医学理论与实践, 2021, 34(23): 4101-4103.
[26]	Su Y, Chen H, Chan T, et al. Disease-modifying anti-rheumatic drugs associated with different diabetes risks in patients with rheumatoid arthritis[J]. RMD Open, 2023, 9(3): e003045.
[27]	Baghdadi LR. Correction: Effect of methotrexate use on the development of type 2 diabetes in rheumatoid arthritis patients: A systematic review and meta-analysis[J]. PloS one, 2020, 15(12): e0243960.
[28]	Lillegraven S, Greenberg JD, Reed GW, et al. Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis[J]. PLoS One, 2019, 14(1): e0210459.
[29]	Semb AG, Rollefstad S, Ikdahl E, et al. Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: An international audit[J]. RMD Open, 2021, 7(2).
[30]	王勇, 姚晓玲, 杨豫正, 等. 两样本孟德尔随机化探讨欧洲类风湿关节炎人群与缺铁性贫血的因果关系[J]. 安徽医科大学学报, 2024, 59(7): 1251-1256.
[31]	黄红, 段利华, 姜林娣, 等. 抗风湿药物胃肠道损伤管理中国专家共识(2024版)[J]. 中华风湿病学杂志, 2024, 28(5): 293-302.
[32]	中华医学会肝病分会药物性肝病学组中华医学会风湿病学分会中国医师协会风湿免疫科医师分会中华中医药学会风湿病分会. 抗风湿病药物性肝损伤诊治中国专家共识(2024年版)[J]. 中华风湿病学杂志, 2024, 63(8): 743-761.
[33]	Reddy SC, Rao UR. Ocular complications of adult rheumatoid arthritis[J]. Rheumatol Int, 1996, 16(2): 49-52. pmid: 8853225
[34]	Gherghe AM, Dougados M, Combe B, et al. Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: Results from the ESPOIR and DESIR cohorts[J]. RMD Open, 2015, 1(1): e000128.
[35]	孙佳宁, 崔轶霞. 类风湿关节炎与抑郁症共病的研究进展[J]. 临床荟萃, 2023, 38(7): 663-667.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 35

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Clinical Focus, 2024, 39(12): 1135-1140.
[2]	Dong Hong, Li Zhenbin, Ma Xu, Luo Yaping, Jiao Aijun, Zhang Xufei, Sun Caixia. Rheumatoid arthritis combined with insomnia: A multicenter cross-sectional survey [J]. Clinical Focus, 2024, 39(10): 882-888.
[3]	Song Yijing, Li Jian, Song Qin, Shao Li. Predictive value of C-reactive protein combined with triglyceride glucose index for coronary heart disease risk in patients with rheumatoid arthritis [J]. Clinical Focus, 2024, 39(6): 506-511.
[4]	. [J]. Clinical Focus, 2023, 38(8): 753-756.
[5]	. [J]. Clinical Focus, 2023, 38(7): 663-667.
[6]	. [J]. Clinical Focus, 2023, 38(3): 279-284.
[7]	Zhang Yueyue, Xie Meifang, Sun Gen. Rheumatoid arthritis complicated with T-cell large granular lymphocytic leukemia: A case report and literature review [J]. Clinical Focus, 2022, 37(8): 728-732.
[8]	Hu Fangfang, Zhong Shiling, Di Yazhen, Wu Ling. Vascular endothelial function of juvenile idiopathic arthritis in pediatric patients: A systematic review and meta-analysis [J]. Clinical Focus, 2022, 37(3): 204-210.
[9]	Lin Changyi, Song Minghui, Wu Peicheng. Difference between remitting seronegative symmetrical synovitis with pitting edema syndrome and seronegative rheumatoid arthritis [J]. Clinical Focus, 2022, 37(3): 262-265.
[10]	. [J]. Clinical Focus, 2022, 37(2): 188-192.
[11]	. [J]. Clinical Focus, 2022, 37(1): 92-96.
[12]	Liu Ziyi, Wang Jibo. Analysis of clinical characteristics and related factors of rheumatoid arthritis complicated with malignant tumors in patients [J]. Clinical Focus, 2021, 36(3): 246-250.
[13]	. [J]. Clinical Focus, 2021, 36(1): 75-79.
[14]	Chen Wenyu, Wang Juanjuan, Wang Zhiming. Clinical feature of pleural effusion in 78 patients with rheumatoid arthritis [J]. Clinical Focus, 2016, 31(2): 214-217.
[15]	Xie Qingyun, Wei Meng, Fu Peiliang, Sun Jiuyi, Qian Qirong. Association study between single nucleotide polymorphisms of interleukin 23 receptor and rheumatoid arthritis [J]. Clinical Focus, 2016, 31(1): 40-44.